The Effects Of Dexmedetomidine On Inflammatory Responses In Patients Undergoing Valve Replacement Surgery With Cardiopulmonary Bypass

Objective: This prospective study was designed to research the effect of dexmedetomidine (DEX) on reducing the inflammation responses of valve replacement surgery patients under cardiopulmonary bypass (CPB) and explore the safety, efficacy and clinical significance of DEX used in this kind of cardiac surgery. Method: 30 patients were randomly divided into two groups: patients in one group (Group D, n=15) received dexmedetomidine 0.5 mu g center dot kg(-1)center dot h(-1) before incision and 0.5 mu g center dot kg(-1)center dot h(-1) intra-operatively, while the control group (Group C, n=15) received the same volume of saline. Venous blood was collected at several time points for the serum content detection of TNF-alpha, IL-6, SOD and MDA. Results: Compared with group C, the content of TNF-alpha in group D declined significantly at time point T-2, T-3, T-4, T-5. The content of serum IL-6 in group D declined significantly at time point T4 and T5. Meanwhile, the serum SOD content in group D was obviously elevated with a significant difference at time point T2, T3, T4 (P < 0.05) and the content of MDA in group D declined significantly at time point T3, T4 and T5 (P < 0.05). Furthermore, the extubation time and the ICU care duration of group D were both significantly shorten compared with group C (P < 0.05). Conclusion: The continuous administration of dexmedetomidine during valve replacement surgery with CPB suppressed intraoperative and post-operative cytokine secretion, and improved post-operative inflammatory response indices in the present study. These results can be attributed to the anti-inflammatory effects of dexmedetomidine.